We have developed optimized strategies to reprogram primary mouse B cells to generate therapeutic antibodies and proteins. Effective transfer and expression of the gene of interest (GOI) is the key step in B cell engineering. Our gene-editing platform and delivery system confers high efficiency of gene transfer into primary mouse B cells, promoting the development of B cell-based therapy.